share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：证券上市注册声明
美股SEC公告 ·  09/04 16:55

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has undergone significant corporate developments over the past year, including a merger with Murphy Canyon Acquisition Corp. on September 22, 2023, which led to its listing on The Nasdaq Global Market under the ticker 'CDT'. The company has authorized a substantial issuance of shares, with up to 250,000,000 shares of common stock and 1,000,000 shares of preferred stock as of December 31, 2023. In the legal arena, Conduit Pharmaceuticals faces a claim from Strand Hanson Limited for advisory fees and stock, which the company is prepared to contest. Additionally, the company has engaged in the sale of unregistered securities, including a private placement of units and the issuance of common stock for services and a licensing agreement with AstraZeneca. The company's leadership is protected by indemnification provisions in its corporate charter and under Delaware law. Financial statements for 2023 and 2022 have been audited, revealing concerns about the company's operational continuity, and past financial statements have been restated to correct errors related to merger expenses.
Conduit Pharmaceuticals Inc. has undergone significant corporate developments over the past year, including a merger with Murphy Canyon Acquisition Corp. on September 22, 2023, which led to its listing on The Nasdaq Global Market under the ticker 'CDT'. The company has authorized a substantial issuance of shares, with up to 250,000,000 shares of common stock and 1,000,000 shares of preferred stock as of December 31, 2023. In the legal arena, Conduit Pharmaceuticals faces a claim from Strand Hanson Limited for advisory fees and stock, which the company is prepared to contest. Additionally, the company has engaged in the sale of unregistered securities, including a private placement of units and the issuance of common stock for services and a licensing agreement with AstraZeneca. The company's leadership is protected by indemnification provisions in its corporate charter and under Delaware law. Financial statements for 2023 and 2022 have been audited, revealing concerns about the company's operational continuity, and past financial statements have been restated to correct errors related to merger expenses.
在过去的一年里，Conduit Pharmaceuticals Inc.经历了重大的公司发展，包括与Murphy Canyon Acquisition Corp.在2023年9月22日进行的合并，使其在纳斯达克全球市场（Nasdaq Global Market）上市，股票代码为'CDT'。截至2023年12月31日，在授权范围内，公司公共股份达到2.5亿股，优先股达到100万股。在法律领域，Conduit Pharmaceuticals面临来自Strand Hanson Limited的咨询费用和股票索赔，该公司准备对此进行争议。此外，该公司进行了非注册证券的销售，包括定向增发和出让股票以换取服务以及与阿斯利康（AstraZeneca）签订的许可协议。公司的领导层受到其公司章程和特拉华州法律的保护。2023年和2022年的财务报表已经经过审计，发现了关于公司运营连续性的问题，并对过去的财务报表进行了重新编制，以纠正与合并费用相关的错误。
在过去的一年里，Conduit Pharmaceuticals Inc.经历了重大的公司发展，包括与Murphy Canyon Acquisition Corp.在2023年9月22日进行的合并，使其在纳斯达克全球市场（Nasdaq Global Market）上市，股票代码为'CDT'。截至2023年12月31日，在授权范围内，公司公共股份达到2.5亿股，优先股达到100万股。在法律领域，Conduit Pharmaceuticals面临来自Strand Hanson Limited的咨询费用和股票索赔，该公司准备对此进行争议。此外，该公司进行了非注册证券的销售，包括定向增发和出让股票以换取服务以及与阿斯利康（AstraZeneca）签订的许可协议。公司的领导层受到其公司章程和特拉华州法律的保护。2023年和2022年的财务报表已经经过审计，发现了关于公司运营连续性的问题，并对过去的财务报表进行了重新编制，以纠正与合并费用相关的错误。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间